FDA approves FILSPARI for rare kidney disease FSGS
The U.S. Food and Drug Administration approved FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)